{"id":"https://openalex.org/W2968738024","doi":"https://doi.org/10.1093/noajnl/vdz014.055","title":"THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES","display_name":"THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES","publication_year":2019,"publication_date":"2019-08-01","ids":{"openalex":"https://openalex.org/W2968738024","doi":"https://doi.org/10.1093/noajnl/vdz014.055","mag":"2968738024"},"language":"en","primary_location":{"id":"doi:10.1093/noajnl/vdz014.055","doi":"https://doi.org/10.1093/noajnl/vdz014.055","is_oa":true,"landing_page_url":"https://doi.org/10.1093/noajnl/vdz014.055","pdf_url":"https://academic.oup.com/noa/article-pdf/1/Supplement_1/i13/34136278/vdz014.055.pdf","source":{"id":"https://openalex.org/S4210237914","display_name":"Neuro-Oncology Advances","issn_l":"2632-2498","issn":["2632-2498"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology Advances","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/noa/article-pdf/1/Supplement_1/i13/34136278/vdz014.055.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000656932","display_name":"Jing Ni","orcid":"https://orcid.org/0000-0002-4229-775X","observed_orcids":["https://orcid.org/0000-0002-4229-775X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Ni","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yanzhi Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanzhi Wang","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015397173","display_name":"Irmina Diala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154785","display_name":"Puma Biotechnology (United States)","ror":"https://ror.org/053kr4v45","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154785"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Irmina Diala","raw_affiliation_strings":["Puma Biotechnology, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Puma Biotechnology, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210154785"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022623760","display_name":"Sheheryar Kairas Kabraji","orcid":"https://orcid.org/0000-0002-5315-7103","observed_orcids":["https://orcid.org/0000-0002-5315-7103"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sheheryar Kabraji","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080530218","display_name":"Rachel A. Freedman","orcid":"https://orcid.org/0000-0003-0460-674X","observed_orcids":["https://orcid.org/0000-0003-0460-674X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Freedman","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy Lin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043714628","display_name":"Jean J. Zhao","orcid":"https://orcid.org/0000-0002-4561-5688","observed_orcids":["https://orcid.org/0000-0002-4561-5688"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Zhao","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2615,"currency":"USD","value_usd":2615},"apc_paid":{"value":2615,"currency":"USD","value_usd":2615},"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"1","issue":"Supplement_1","first_page":"i13","last_page":"i13"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.8241999745368958,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.8241999745368958,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.13729999959468842,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/breast-cancer-brain-metastases","display_name":"breast cancer brain metastasis","score":0.9769999980926514},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9869999885559082},{"id":"https://openalex.org/keywords/neratinib","display_name":"neratinib","score":1.0},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.9079999923706055},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6819999814033508},{"id":"https://openalex.org/keywords/her2-tyrosine-kinase-inhibitor","display_name":"HER2 tyrosine kinase inhibitor","score":0.8009999990463257},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8399999737739563},{"id":"https://openalex.org/keywords/blood-brain-barrier-penetration","display_name":"blood-brain barrier penetration","score":0.7870000004768372},{"id":"https://openalex.org/keywords/her2-phosphorylation","display_name":"HER2 phosphorylation","score":0.8809999823570251},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.7300000190734863},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.7820000052452087}],"concepts":[{"id":"https://openalex.org/C2779413316","wikidata":"https://www.wikidata.org/wiki/Q6995920","display_name":"Neratinib","level":5,"score":0.9944955110549927},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7200519442558289},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.7155557870864868},{"id":"https://openalex.org/C2778087150","wikidata":"https://www.wikidata.org/wiki/Q3997863","display_name":"Trastuzumab emtansine","level":5,"score":0.6376717686653137},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5487455129623413},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5366031527519226},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.49046704173088074},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4502420723438263},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4409520924091339},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4273689389228821},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.38784679770469666}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/noajnl/vdz014.055","doi":"https://doi.org/10.1093/noajnl/vdz014.055","is_oa":true,"landing_page_url":"https://doi.org/10.1093/noajnl/vdz014.055","pdf_url":"https://academic.oup.com/noa/article-pdf/1/Supplement_1/i13/34136278/vdz014.055.pdf","source":{"id":"https://openalex.org/S4210237914","display_name":"Neuro-Oncology Advances","issn_l":"2632-2498","issn":["2632-2498"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology Advances","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7213268","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7213268","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurooncol Adv","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/noajnl/vdz014.055","doi":"https://doi.org/10.1093/noajnl/vdz014.055","is_oa":true,"landing_page_url":"https://doi.org/10.1093/noajnl/vdz014.055","pdf_url":"https://academic.oup.com/noa/article-pdf/1/Supplement_1/i13/34136278/vdz014.055.pdf","source":{"id":"https://openalex.org/S4210237914","display_name":"Neuro-Oncology Advances","issn_l":"2632-2498","issn":["2632-2498"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8799999952316284,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2968738024.pdf","grobid_xml":"https://content.openalex.org/works/W2968738024.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2955877694","https://openalex.org/W4403284220","https://openalex.org/W4400381789","https://openalex.org/W4322769470","https://openalex.org/W4411287694","https://openalex.org/W4387410042","https://openalex.org/W2598258962","https://openalex.org/W2885137441","https://openalex.org/W4362593083","https://openalex.org/W4400915522"],"abstract_inverted_index":{"Abstract":[0],"Breast":[1],"cancer":[2,56],"brain":[3],"metastases":[4],"(BCBM)":[5],"are":[6,97],"a":[7,259],"major":[8],"cause":[9],"of":[10,82,173,217,227,244,258,270],"morbidity":[11],"and":[12,20,134,147,230,246,268],"mortality,":[13],"despite":[14],"multimodal":[15],"management":[16],"including":[17],"surgery,":[18],"radiotherapy,":[19],"systemic":[21],"therapies.":[22],"There":[23],"is":[24,34,44,61,112,204],"an":[25,35,62,119],"urgent":[26],"need":[27],"to":[28,84,101,114,161,182,206,240,248,264],"develop":[29],"novel,":[30],"efficacious":[31],"alternatives.":[32],"Neratinib":[33],"orally":[36],"bioavailable,":[37],"irreversible":[38],"pan-HER":[39],"tyrosine":[40],"kinase":[41],"inhibitor":[42],"that":[43,110,128],"FDA-approved":[45],"in":[46,106,118,138,143,194,209,231,235,250,272,276],"the":[47,132,201,215,256,266],"extended":[48],"adjuvant":[49],"treatment":[50,172,185,203],"setting":[51],"for":[52],"HER2-positive,":[53],"early":[54],"breast":[55],"(NCT00878709).":[57],"Ado-trastuzumab":[58],"emtansine":[59],"(T-DM1)":[60],"antibody-drug":[63],"conjugate":[64],"with":[65,89,99,175,186,233,274,278],"reported":[66],"single-agent":[67],"activity":[68],"against":[69],"HER2-positive":[70,75,125,145,251,280],"BCBM.":[71,281],"Here,":[72],"we":[73],"used":[74],"orthotopic":[76,120,157],"patient":[77],"derived":[78,123],"xenograft":[79],"(PDX)":[80],"models":[81,239],"BCBM":[83,139,237],"test":[85,265],"if":[86],"combining":[87],"neratinib":[88,111,129,153,174,187,228,275],"T-DM1":[90,176,189,207,234,271],"could":[91],"improve":[92],"tumor":[93,103,122,158,179],"response.":[94],"PDX":[95,121,140,149,238],"cells":[96],"labelled":[98],"luciferase":[100],"allow":[102],"growth":[104,159,180],"measurement":[105],"vivo.":[107],"We":[108],"found":[109],"able":[113],"reduce":[115],"phosphorylated":[116],"HER2":[117,136],"from":[124],"BCBM,":[126],"indicating":[127],"can":[130],"cross":[131],"BBB":[133],"inhibit":[135],"activation":[137],"tissues.":[141],"However,":[142],"both":[144,195],"DF-BM354":[146,210],"DF-BM355":[148,220],"models,":[150],"single":[151,183],"agent":[152,184],"did":[154],"not":[155],"block":[156],"compared":[160,181],"vehicle":[162],"control":[163],"as":[164],"monitored":[165],"by":[166],"bioluminescence":[167],"measurements.":[168],"In":[169],"contrast,":[170],"combined":[171,202],"significantly":[177,213],"reduced":[178],"or":[188],"at":[190],"earlier":[191],"time":[192,199],"points":[193],"models.":[196],"At":[197],"later":[198],"points,":[200],"comparable":[205],"alone":[208,229],"model,":[211],"but":[212],"prolong":[214],"survival":[216],"mice":[218],"bearing":[219],"tumors.":[221],"These":[222],"data":[223],"warrant":[224],"further":[225],"testing":[226],"combination":[232,273],"additional":[236],"better":[241],"understand":[242],"drivers":[243],"resistance":[245],"susceptibility":[247],"HER2-inhibitors":[249],"BCBMs.":[252],"Furthermore,":[253],"they":[254],"support":[255],"launch":[257],"prospective":[260],"clinical":[261],"trial":[262],"(NCT01494662)":[263],"efficacy":[267],"tolerability":[269],"patients":[277],"progressive":[279]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-08-22T00:00:00"}